Home >> Research Area >>Natural Products>>Diterpenoids>> 18-Norabieta-8,11,13-trien-4-ol

18-Norabieta-8,11,13-trien-4-ol

CAS# 22478-65-5

18-Norabieta-8,11,13-trien-4-ol

Catalog No. BCN5064----Order now to get a substantial discount!

Product Name & Size Price Stock
18-Norabieta-8,11,13-trien-4-ol: 5mg Please Inquire In Stock
18-Norabieta-8,11,13-trien-4-ol: 10mg Please Inquire In Stock
18-Norabieta-8,11,13-trien-4-ol: 20mg Please Inquire Please Inquire
18-Norabieta-8,11,13-trien-4-ol: 50mg Please Inquire Please Inquire
18-Norabieta-8,11,13-trien-4-ol: 100mg Please Inquire Please Inquire
18-Norabieta-8,11,13-trien-4-ol: 200mg Please Inquire Please Inquire
18-Norabieta-8,11,13-trien-4-ol: 500mg Please Inquire Please Inquire
18-Norabieta-8,11,13-trien-4-ol: 1000mg Please Inquire Please Inquire

Quality Control of 18-Norabieta-8,11,13-trien-4-ol

Number of papers citing our products

Chemical structure

18-Norabieta-8,11,13-trien-4-ol

3D structure

Chemical Properties of 18-Norabieta-8,11,13-trien-4-ol

Cas No. 22478-65-5 SDF Download SDF
PubChem ID 15605917 Appearance Powder
Formula C19H28O M.Wt 272.4
Type of Compound Diterpenoids Storage Desiccate at -20°C
Solubility Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
Chemical Name (1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-ol
SMILES CC(C)C1=CC2=C(C=C1)C3(CCCC(C3CC2)(C)O)C
Standard InChIKey SOJWLJKPIIODOH-GUDVDZBRSA-N
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of 18-Norabieta-8,11,13-trien-4-ol

The herbs of Pinus yunnanensis

18-Norabieta-8,11,13-trien-4-ol Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

18-Norabieta-8,11,13-trien-4-ol Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of 18-Norabieta-8,11,13-trien-4-ol

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.6711 mL 18.3554 mL 36.7107 mL 73.4214 mL 91.7768 mL
5 mM 0.7342 mL 3.6711 mL 7.3421 mL 14.6843 mL 18.3554 mL
10 mM 0.3671 mL 1.8355 mL 3.6711 mL 7.3421 mL 9.1777 mL
50 mM 0.0734 mL 0.3671 mL 0.7342 mL 1.4684 mL 1.8355 mL
100 mM 0.0367 mL 0.1836 mL 0.3671 mL 0.7342 mL 0.9178 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on 18-Norabieta-8,11,13-trien-4-ol

The characteristics of coronary stenosis in 11,267 patients from Southwest China: a retrospective study.[Pubmed:29019045]

J Thromb Thrombolysis. 2018 Jan;45(1):142-150.

The characteristics of coronary stenosis vary among the different countries or areas. 11,267 patients who have undergone coronary angiography (CAG) from three Southwest China hospitals were investigated. Patient characteristics, coronary stenosis and stent-implant information were recorded and analyzed according to two criteria: "visible stenosis" and ">/= 50% stenosis". The patients who have undergone CAG increased year by year, with patients from 60 to 69 years-old taking the highest ratio (34.69%). Based on the ">/= 50% stenosis" criteria, the stenotic frequency was 40.54% for Southwest China patients getting CAG. Only 8.14% patients suffered >/= 3 stenotic vessels, while 11.58 and 20.82% patients had 2 or 1 stenotic vessel, respectively. However, when using the "visible stenosis" criteria, the stenotic frequency increased to 64.68%. The prevalence of stenosis increased with age based on the "visible stenosis" criteria. There were more male patients with stenosis than female except patients over 80 years old. The stenosis affected almost all main coronary arteries and their branches, with the most affected artery being the left anterior descending artery. There were 3246 cases (28.8%) implanted with 5423 stents with a concurrent age-dependent increasing tendency for stent-implant frequency and average implanted stent number. The numbers of patients who have undergone CAG and suffered from CVD increased rapidly. In these patients, positive rate of CAG was 64.67%, which increased to 72.2% in patients over 60-years old. The incidence of >/= 75% stenosis and multiple stenosis increased with age, however it should be noticed there were 18.93% for >/= 75% stenosis and 19.52% for multiple stenosis in patients under 40 years old.

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.[Pubmed:29018077]

Blood. 2017 Nov 30;130(22):2401-2409.

Venetoclax is a selective, orally bioavailable BCL-2 inhibitor that induces cell death in multiple myeloma (MM) cells, particularly in those harboring t(11;14), which express high levels of BCL-2 relative to BCL-XL and MCL-1. In this phase 1 study, patients with relapsed/refractory MM received venetoclax monotherapy. After a 2-week lead-in with weekly dose escalation, daily venetoclax was given at 300, 600, 900, or 1200 mg in dose-escalation cohorts and 1200 mg in the safety expansion. Dexamethasone could be added on progression during treatment. Sixty-six patients were enrolled (30, dose-escalation cohorts; 36, safety expansion). Patients received a median of 5 prior therapies (range, 1-15); 61% were bortezomib and lenalidomide double refractory, and 46% had t(11;14). Venetoclax was generally well tolerated. Most common adverse events included mild gastrointestinal symptoms (nausea [47%], diarrhea [36%], vomiting [21%]). Cytopenias were the most common grade 3/4 events, with thrombocytopenia (32%), neutropenia (27%), anemia (23%), and leukopenia (23%) reported. The overall response rate (ORR) was 21% (14/66), and 15% achieved very good partial response or better (>/=VGPR). Most responses (12/14 [86%]) were reported in patients with t(11;14). In this group, ORR was 40%, with 27% of patients achieving >/=VGPR. Biomarker analysis confirmed that response to venetoclax correlated with higher BCL2:BCL2L1 and BCL2:MCL1 mRNA expression ratios. Venetoclax monotherapy at a daily dose up to 1200 mg has an acceptable safety profile and evidence of single-agent antimyeloma activity in patients with relapsed/refractory MM, predominantly in patients with t(11;14) abnormality and those with a favorable BCL2 family profile. Registered at www.clinicaltrials.gov: #NCT01794520.

Keywords:

18-Norabieta-8,11,13-trien-4-ol,22478-65-5,Natural Products, buy 18-Norabieta-8,11,13-trien-4-ol , 18-Norabieta-8,11,13-trien-4-ol supplier , purchase 18-Norabieta-8,11,13-trien-4-ol , 18-Norabieta-8,11,13-trien-4-ol cost , 18-Norabieta-8,11,13-trien-4-ol manufacturer , order 18-Norabieta-8,11,13-trien-4-ol , high purity 18-Norabieta-8,11,13-trien-4-ol

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: